Rapport Therapeutics Inc(RAPP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.04 | Insider Own | 39.96% | Shs Outstand | 48.0M | Perf Week | -5.14% |
| Market Cap | 1.37B | Forward P/E | - | EPS next Y | -22.28% | Insider Trans | -5.19% | Shs Float | 28.8M | Perf Month | -29.3% |
| Enterprise Value | 0.95B | PEG | - | EPS next Q | -1.2 | Inst Own | 75.23% | Short Float | 11.09% | Perf Quarter | -32.8% |
| Income | -0.14B | P/S | 68.61 | EPS this Y | -40.23% | Inst Trans | 0.71% | Short Ratio | 9.08 | Perf Half Y | -22.99% |
| Sales | 0.02B | P/B | 3.24 | EPS next 5Y | -23.65% | ROA | -36.85% | Short Interest | 3.19M | Perf YTD | -5.74% |
| Book/sh | 8.82 | P/C | 3.15 | EPS past 3/5Y | -114.24% - | ROE | -39.96% | 52W High | -45.97% ($52.93) | Perf Year | 14.45% |
| Cash/sh | 9.09 | P/FCF | - | Sales past 3/5Y | - | ROIC | -31.86% | 52W Low | 20.42% ($23.75) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -23.53% | Gross Margin | 95.2% | Volatility(W/M) | 6.25% 7.01% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 47.31 | Sales Y/Y TTM | - | Oper. Margin | -767.58% | ATR (14) | 2.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.72 | EPS Q/Q | -58.13% | Profit Margin | -685.8% | RSI (14) | 29.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.72 | Sales Q/Q | - | SMA20 | -10.11% ($31.82) | Beta | 1.3 | Target Price | $62.87 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/5 | SMA50 | -29.78% ($40.73) | Rel Volume | 0.85 | Prev Close | $27.57 |
| Employees | 84 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -23.56% - | SMA200 | -20% ($35.75) | Avg Volume(3M) | 0.35M | Price | $28.6 |
| IPO | 2024/6/7 | Option/Short | Yes/Yes | Trades | 3853 | Volume | 300,734 | Change | 3.74% |
🧠 This is a US clinical-stage biotech company developing precision neuroscience-based therapeutics. Using technology that precisely targets specific sites of neural receptors, it develops candidates targeting neurological disorders such as epilepsy and neuropathic pain, and holds a lead candidate in late-stage clinical trials. The company is a biotech that is entering the underserved neurological disorder market with a differentiated precision neuroscience approach.
Over the past 1 year, on the lower side
46% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
RAPP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -40.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,861. Peers typically go for $1,078.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 75.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #128 of 595 in the industry
Based on market cap of $1B.
KRSA#126 Korsana Biosciences Inc $1B PER - 
OCUL#127 Ocular Therapeutix Inc $1B PER - RAPP#128 Rapport Therapeutics Inc $1B PER - 
INBX#129 Inhibrx Biosciences Inc $1B PER - 
ORIC#130 ORIC Pharmaceuticals Inc $1B PER - 
FAQ
What kind of company is RAPP?
RAPP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RAPP?
The market cap of RAPP is approximately $1.4B, ranking 2,330 within its sector.
What is the 52-week high and low for RAPP?
RAPP has recorded a 52-week high of $52.93 and a low of $23.75.
